efavirenz

cytochrome P450 family 2 subfamily B member 6 ; Homo sapiens







123 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34873089 Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age. 2022 Mar 15 1
2 35099526 Corrigendum to: CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. 2022 Mar 1 1
3 35115810 The Cyp2b6 Gene Polymorphism and Phenotypic Correlation of Efavirenz-Based Combination Therapy Among the Niger Delta Ethnic Population: Implications in Modern Pharmacogenomics. 2022 2
4 35194103 CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function. 2022 Feb 22 1
5 35235559 Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya. 2022 2
6 35512066 The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana. 2022 Apr 29 1
7 32667979 Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens. 2021 May 18 1
8 32815870 Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. 2021 Jan 1
9 32829410 Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. 2021 Oct 5 5
10 32909316 Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. 2021 Apr 1
11 32960272 CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. 2021 Dec 6 4
12 33336382 Metamizole is a Moderate Cytochrome P450 Inducer Via the Constitutive Androstane Receptor and a Weak Inhibitor of CYP1A2. 2021 Jun 1
13 33599403 Allelic and genotype frequencies of major CYP2B6 polymorphisms in the Pakistani population. 2021 Mar 1
14 33758532 Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana. 2021 3
15 33833550 Erratum: Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana [Corrigendum]. 2021 1
16 33872945 Identification of miRNAs that regulate human CYP2B6 expression. 2021 Jun 2
17 34093191 Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy. 2021 2
18 34115651 Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. 2021 Oct 1 3
19 34415664 Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. 2021 Nov 1
20 34474119 Effect of albumin and CYP2B6 polymorphisms on exposure of efavirenz: A population pharmacokinetic analysis in Chinese HIV-infected adults. 2021 Dec 1 6
21 34882770 Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS). 2021 Nov 19 2
22 34945777 Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study. 2021 Dec 5 2
23 31628422 Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers. 2020 Apr 5
24 32106141 Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives. 2020 Apr 6
25 32377759 Prediction of the exposure to a 400-mg daily dose of efavirenz in pregnancy: is this dose adequate in extensive metabolisers of CYP2B6? 2020 Aug 1
26 32451120 Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. 2020 Jul 4
27 32838647 Pharmacogenomics and pharmacokinetics of efavirenz 400 or 600 mg in 184 treatment-naive HIV-infected patients in China. 2020 Aug 1
28 33355828 Prevalence of Cytochrome P450 2B6 Single Nucleotide Polymorphism in an HIV-Positive Cohort in Jos, Nigeria: Implication for HIV Therapy. 2020 Dec 3
29 30535366 Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites. 2019 Mar 1 1
30 31006110 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. 2019 Oct 3
31 31241542 Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years. 2019 Aug 1 2
32 31243456 Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing. 2019 Sep 1 1
33 31299074 Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. 2019 Oct 1 2
34 31324697 Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry. 2019 Oct 20
35 29629676 A proposed management algorithm for late-onset efavirenz neurotoxicity. 2018 Mar 28 2
36 29635009 The impact of CYP2B6 polymorphisms on the interactions of efavirenz with lumefantrine: Implications for paediatric antimalarial therapy. 2018 Jul 1 1
37 29636682 Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz. 2018 1
38 29855606 Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana. 2018 Sep 1
39 29868865 Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals. 2018 Sep 1 1
40 30201214 Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation. 2018 Oct 4
41 27799204 Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. 2017 Jan 1
42 28403028 Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings. 2017 Jul 1
43 28481785 Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana. 2017 Aug 1 2
44 28559276 Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. 2017 Aug 1
45 28718515 Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. 2017 Sep 1
46 26553012 In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid. 2016 Jan 3
47 26655325 CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women. 2016 Jun 2
48 26831894 Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation. 2016 Feb 2 1
49 26891286 Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral Therapy (HAART) in Resource-Limited Settings. 2016 Feb 16 2
50 27045425 CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. 2016 Apr 2